Altman Peter purchased $5K of BCDA
Altman Peter (President and CEO) purchased 5,400 shares of BioCardia, Inc. (BCDA) at $0.93 on 2026-08-17.
How this was made
The 30-second read
Why it matters
The newest fact is the CEO’s open-market purchase details (5,400 shares at $0.93) and the absence of a pre-arranged 10b5-1 plan, which can slightly increase perceived conviction but does not change fundamentals by itself.
Market read
Traders may note the insider buy as a minor sentiment input, but there is no guidance, trial, deal, or regulatory catalyst in the text.
What to watch
The article provides no context on prior insider activity, total insider ownership changes over time, or whether the purchase size is meaningful versus typical CEO buying patterns.
Background
The article is an SEC Form 4 insider transaction disclosure for BioCardia, Inc. (BCDA).
Ticker impact
BioCardia CEO Altman Peter filed a Form 4 open-market purchase of 5,400 shares at $0.93 on 2026-08-17.
Likely limited near-term price impact; any effect is sentiment-driven and typically fades unless followed by larger actions or company catalysts.
The filing is a routine insider open-market purchase with no 10b5-1 plan and no accompanying operational or financial disclosure in the text.
Market effects
No sector-level implications from a single small insider purchase.
None indicated.
None indicated.
Counterpoint
Insider open-market buys are often discretionary and can be driven by liquidity needs or diversification rather than a strong forward-looking view.
Key entities
- issuerBioCardia, Inc.
Subject of the Form 4 insider transaction disclosure.
- insiderAltman Peter
President and CEO who reported the purchase.
